Aim to Alleviate Alopecia Areata With Newly Available Agents

The article discusses the treatment of alopecia areata (AA), an autoimmune condition causing hair loss, traditionally managed with corticosteroids that have limited efficacy and adverse effects. Recently, janus kinase inhibitors (JAKIs) like baricitinib and ritlecitinib have been approved, offering new hope for AA treatment. These agents, along with other emerging therapies such as monoclonal antibodies and targeted immune modulators, could change current treatment protocols. However, a better understanding of their adverse drug events is necessary, as ongoing trials continue to investigate these aspects.